Measurement of soluble (s) P-selectin levels has been proposed as a diagnostic tool for monitoring the clinical course of human neoplasms. Thus, our study was aimed at analyzing the role of sP-selectin in association with clinicopathological variables in 181 patients with primary (n‫)941؍‬ or metastatic (n‫)23؍‬ colorectal cancer (CRC), 34 patients with benign diseases and 181 control subjects. The results obtained showed that sP-selectin levels were higher in patients with CRC compared either to patients with benign disease (p‫؍‬ 0.006) or controls (p‫؍‬ 0.003). No differences were observed between the latter and patients with benign diseases. Increased median sP-selectin levels were significantly associated with the presence of distant metastasis (68.2 ng/ml vs. 48.6 ng/ml, p‫؍‬ 0.002). Of interest, carcinoembryonic antigen (CEA) levels were independently associated to sP-selectin (regression coefficient‫؍‬ 0.28, p< 0.002). Cox's proportional hazards survival analysis of primary CRC patients demonstrated that beside the stage of disease sP-selectin levels had an independent prognostic role in predicting recurrent disease (HR‫؍‬ 2.22, p‫؍‬ 0.019) and mortality from CRC (HR‫؍‬ 3.44, p‫؍‬ 0.017). These results suggest that measurement of plasma sP-selectin might represent a prognostic indicator in the management of patients with CRC.
Blood-borne metastasis is a highly regulated and dynamic process in which cancerous cells separate from a primary tumor, migrate across blood vessel walls into the bloodstream and disperse throughout the body to generate new colonies. During their transit into the circulatory system, tumor cells are exposed to vascular cells such as platelets, endothelial cells and neutrophils, all of which may engage adhesive interactions with tumor cells, thus affecting their survival and extravasation from the vasculature.
Selectins are adhesion molecules that mediate calcium-dependent cell-cell interactions among leukocytes (L-selectin), platelets (P-selectin) and endothelial cells (P-and E-selectin). 1 It was previously shown that sP-selectin binds to colon carcinoma cell lines and that carcinoma growth and metastasis formation are attenuated in P-selectin-deficient mice. [2] [3] [4] [5] More recently, it has been suggested that platelets and/or endothelial cells might primarily recruit colorectal cancer (CRC) cells through a 2-step, sequential process of adhesive interactions, involving selectins, that shares common features but is distinct from that elaborated for neutrophils. 2, 6 All these findings could explain some of the adhesive events of bloodborne tumor cells reported to occur with platelets, and endothelial cells, which are believed to play a part in modulating some early events in tumor metastases.
Increased expression of P-selectin by vascular endothelial cells has been found in human colon cancer 7 and has been related to the immune/inflammatory reaction often associated to colorectal carcinoma. Moreover, elevated levels of soluble (s)P-selectin have been found in some human neoplastic disorders, such as lung 8 and breast cancer, 9 melanoma 10 and hematological malignancies, 9, 11 and it has been suggested that measurement of sP-selectin may provide a sensitive tool for monitoring the clinical course of melanoma and lymphoma. 10, 11 To date, no clinical information is available on the behavior of sP-selectin in CRC. sP-selectin basal level in the healthy individual is essentially endothelial cell derived, 12 but any increase above the basal level has been related to platelet activation. 13 It is currently recognized that approximately 50% of all cancer patients display abnormalities of the haemostatic system, including platelet functional abnormalities. 14 Moreover, we have recently demonstrated that elevated sP-selectin levels are found in approximately 30% of other cancer patients. 15 Thus, we assumed that a similar percentage of CRC patients may also have increased levels of this adhesion molecule. In this light, the present study was designed to analyze the behavior of presurgical plasma sP-selectin levels in patients with different stages of CRC compared to patients with benign diseases as well as to control subjects. The concomitant measurement of plasma sE-selectin levels (a marker of endothelial dysfunction) was included as a comparator molecule to assess the platelet origin of sP-selectin. Moreover, a follow-up study of primary CRC patients who underwent surgical resection with curative intent was performed to analyze the possible prognostic value of pre-surgical sP-selectin levels in predicting the diseasefree and overall survival of patients with CRC.
METHODS

Patients
Two hundred fifteen patients with either benign (nϭ34) or malignant (nϭ181) colorectal diseases, treated at our Institutions, entered into the study. The 149 patients diagnosed with primary CRC (86 males, 63 females, mean age 62.5 Ϯ 10.3 years) were followed from the time of diagnosis of primary tumor for at least 3 years after surgery. All patients were generally reviewed at 3-month intervals during the first 2 years after surgery. Thereafter, the interval between visits increased to 6 or 12 months in parallel with tumor stage. The study was performed under the appropriate institutional ethics approvals and in accordance with the principles embodied in the Declaration of Helsinki. Written informed consent was obtained from each subject.
Sample collection and immunoassays
Blood samples from primary CRC patients were drawn within 1 week before surgery, or prior to neoadjuvant chemotherapy and/or irradiation. Samples from patients with metastatic disease were obtained at the time of clinical diagnosis, and prior to any treatment. Serum samples from patients with benign disease were drawn at time of endoscopy. After an overnight fast and a rest of at least 20 min, blood was drawn from each consenting subject by venipuncture of the antecubital vein using a 20G needle. Blood was then collected into Na citrate 3.8% (1:9, v:v) and immediately centrifuged at 1,500g for 15 min at room temperature. Plasma samples were aliquoted, coded and stored at Ϫ40°C until the assays were performed.
sP-selectin and sE-selectin levels were measured by enzymeimmunometric assays (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. Intra-and inter-assay coefficients of variation were below 5% and 10%, respectively, for both assays. The minimum detectable doses for sP-selectin and sE-selectin were 0.5 ng/ml and 0.1 ng/ml, respectively. The cut-off value for sP-selectin was set at 75 ng/ml according to the mean value ϩ2 SD of the levels observed in the 181 control subjects.
Serum carcinoembryonic antigen (CEA) levels were measured using a commercially available immunoassay (Abbott Labs, Chicago, IL). CA 72-4 and CA 19-9 levels were determined using the CA 72-4 DDRIA and the CA 19-9 RIA Kits (both by Fujirebio Diagnostics, Inc., formerly Centocor Diagnostics, Malvern, PA). The cut-off limits chosen for sample evaluation were 5 ng/ml, 6 U/ml and 37 U/ml for CEA, CA 72-4 and CA 19-9, respectively. Measurements were done blinded. All samples were assayed in duplicate and those showing values above the standard curve were retested with appropriate dilutions.
Statistical analysis
Sample size of the study was based on the agreement to inclusion criteria and willingness to provide informed consent rather than on sample-size calculations. However, estimation was later performed and suggested that at least 100 patients per group is an appropriate sample size in the case-control study, assuming a 30% difference in sP-selectin levels between patients and control subjects, using a 2-tailed (alpha) of .05 and 95% power.
Data are generally presented as percentage of positive patients. Unless otherwise specified, antigen levels are expressed as median and interquartile range (IQR). Statistical analysis was performed by Kruskal-Wallis test followed by Mann-Whitney U test for post-hoc comparison. Differences between percentages were assessed by cross tabulation tables and chi-square analysis. Multiple regression analysis was used to assess the differences and relationships between continuous variables. Univariate and multivariate analyses were performed by Cox's proportional hazard model: the first step was performed by the Log Rank Test and then the covariates found to be associated with the outcome variables were included in the Cox's regression model. For each variable, the proportional hazard has been tested. Clinical and laboratory variables considered in the analysis were age, sex, tumor location, grading, tumor stage, serum tumor markers and plasma sP-selectin levels. The variables that achieved statistical significance in the univariate analysis were subsequently included in a multivariate analysis using a Cox regression model. Only p values lower than 0.05 were regarded as statistically significant. All calculations were made using computer software packages (Statistica 5.5, StatSoft, Inc., Tulsa, OK and EGRET Cytel Software-Co., Cambridge, MA).
RESULTS
Plasma samples from 396 subjects, including 181 healthy subjects and 215 patients with either malignant (nϭ181) or benign (nϭ34) colorectal diseases, were analyzed for the presence of sP-selectin. As shown in Table I , plasma sP-selectin (KruskalWallis test: Hϭ 12.7, pϭ 0.0018) levels were significantly higher in patients with CRC compared to either controls or patients with benign disease, whereas no difference was observed between the 2 latter groups (Table I) . Furthermore, positive sP-selectin levels (above the cutoff value of 75 ng/ml) were observed in approximately 21% of CRC patients compared to 6% of patients with benign disease and 1% of control subjects (chi-squareϭ 38.6, pϽ 0.0001). No significant differences were observed within the 3 groups with respect to gender and age (data not shown). Plasma sE-selectin levels were higher in CRC patients (53.3 Ϯ 28.3 ng/ml) compared to either controls (34.7 Ϯ 13.9 ng/ml, pϽ0.001) or patients with benign disease (33.2 Ϯ 13.5 ng/ml, pϽ0.001), which is in agreement with previously published observations. 16 As expected, sE-selectin levels did not correlate with sP-selectin levels (R s ϭ Ϫ0.024, pϭ 0.85), corroborating the hypothesis of the platelet origin of the latter.
The relationship between plasma sP-selectin and clinical staging of CRC was also evaluated (Table II) . As shown, no significant association was found between sP-selectin levels and the stage of disease, but elevated levels of sP-selectin were found in relapsing patients with distant metastasis (Table II) . In fact, while approximately 18% of patients with primary CRC had positive plasma sP-selectin levels, this percentage was doubled in metastatic patients (chi-squareϭ 4.2, pϭ 0.04). Moreover, the median plasma sP-selectin level for metastatic CRC patients was significantly higher than that obtained in patients with primary CRC (68.2 ng/ml vs., 48.6 ng/ml, pϭ 0.002).
To further analyze the relationship between sP-selectin and clinicopathologic variables of CRC a multiple regression analysis including age, sex, tumor location, grading, stage and tumor marker levels was carried out. The final model obtained by step- .7)]. Two (1%) patients died of nonrelated causes and thus were excluded from all subsequent analyses. No differences were observed in age, sex or site of primary tumor between patients with and without recurrence (data not shown). Presurgical sP-selectin levels were above the cut-off in approximately 28% of relapsing patients compared to 13% (pϭ 0.024) of patients who remained free of disease. Moreover, the median presurgical sP-selectin levels increased from 48.4 ng/ml in patients who remained free of disease and 41.8 ng/ml in locally relapsing patients to 54.5 ng/ml in patients who developed distant metastasis (Hϭ4.9, pϭ 0.08) (Fig. 1) . Univariate analysis of clinicopathologic variables and presurgical levels of sP-selectin and tumor markers demonstrated that relapse-free survival was affected by the Dukes' stage of disease (pϽ 0.001) and by pre-surgical levels of plasma sP-selectin (pϭ 0.034) and serum CEA (pϭ 0.024) or CA 19-9 (pϭ 0.012) (Table III) . Multivariate analysis obtained by the Cox regression model confirmed the independent prognostic role, in predicting relapsing disease, of stage (pϽ 0.001) and sP-selectin levels (pϭ 0.019) (Table III) .
To further analyze the prognostic value of sP-selectin in CRC a Cox proportional hazards survival analysis of the mortality rates was also performed. As shown in Table IV , Dukes' stage (pϽ 0.001) and presurgical levels of both plasma sP-selectin (pϭ 0.017) and serum CEA (pϭ 0.045) had an independent prognostic value in predicting mortality (Table IV) . Of interest, when a risk-set stratification for the Dukes' stage of disease was applied to the model, only sP-selectin levels (Hazard Ratio ϭ 6.0, 95%C.I.: 1.9 -18.5, pϭ 0.002) had an independent prognostic role in predicting mortality. Figure 2 demonstrates the Kaplan-Meier curves for patients with positive (above the cut-off value) or negative (below the cut-off values) sP-selectin levels. As shown, positive presurgical sP-selectin (Log-Rank Statisticϭ 6.143, pϭ 0.013) levels were associated with an increased mortality rate compared to patients with negative levels of this variable.
DISCUSSION
The results obtained in our study demonstrated for the first time that presurgical sP-selectin levels are increased in patients with CRC as compared to either control subjects or patients with benign diseases. Nevertheless, sP-selectin levels were not related to tumor location, grading or Dukes' stages but were significantly associated to the presence of distant metastasis. The lack of correlation between sP-selectin and the stage of disease suggests that the increased sP-selectin levels observed in CRC are not due to the tumor itself but are most likely related to the occurrence of in vivo platelet activation, which is in agreement with the current knowledge that any increase of sP-selectin above the basal level is due to platelet activation. 13 Moreover, the observation that plasma levels of sE-selectin (a well-known marker of endothelial activation) were not correlated with those of sP-selectin in patients with CRC corroborates the hypothesis that the increased levels of sP-selectin found in CRC patients are derived from platelets rather than endothelial cells as a result of in vivo platelet activation. Indeed, subclinical changes in the haemostatic system have been reported in CRC, 14, 17 and a systemic coagulation reactivation has been found in patients with recurrence of CRC previously resected with curative intent. 17 Thus, it appears conceivable to hypothesize that a subclinical activation of coagulation might be responsible for platelet activation, 18 with a mechanism similar, at least in part, to that observed in other human diseases. 15, 19 Besides this possible explanation, the occurrence of enhanced sP-selectin levels in CRC might also be justified by the finding here reported that CEA levels were independently related to sPselectin, suggesting that the former might play a direct role in the mechanism(s) inducing sP-selectin elevation in CRC. To date, no information is available whether CEA is capable of directly activating platelets through adhesive interactions. On the other hand, it is well known that CEA is able to induce the synthesis and release of inflammatory cytokines, i.e., interleukin-6 (IL-6), IL-1␤ and Tumor Necrosis Factor-␣ (TNF-␣). 20, 21 All these cytokines may play a pivotal role in the pathogenesis of the prothrombotic state associated to human cancer, probably acting through induction of tissue factor expression by monocytes and/or endothelial cells. 22 Indeed, CEA-induced IL-1␤ and TNF-␣ are responsible for endothelial cell activation and consequent switch to an adhesive phenotype, 23, 16 which is accompanied by a loss of anti-thrombotic properties of the endothelium. All these phenomena may ultimately favor the hematogenous spread of CRC cells.
In this light, the results obtained in the longitudinal study are of interest. To date, no study was specifically conducted to evaluate the prognostic value of sP-selectin in CRC. In our study, a postsurgical follow-up of primary CRC patients was performed to specifically address this issue. It is worth noticing that of the 53 patients who had recurrent disease, 28% had positive presurgical sP-selectin levels compared to approximately 13% of patients who remained free of disease. Furthermore, the mean presurgical plasma sP-selectin levels were higher in relapsing patients compared to patients who remained free of disease throughout the follow-up. Positive sP-selectin levels were associated with a worse relapse-free survival and a higher mortality rate when compared to negative cases using univariate analysis. Moreover, Cox's proportional hazards survival analysis confirmed the independent prognostic value of elevated presurgical plasma sP-selectin levels in predicting recurrence as well as mortality from CRC.
In conclusion, we believe that our results support the concept that soluble adhesion molecules may play a pivotal role in the pathogenesis of blood-borne metastasis. We are aware that this hypothesis requires detailed experimental evaluation before its ultimate significance can be determined; nevertheless, we hope that our study will prompt investigators to design new studies to better understand the significance of sP-selectin in the disease progression, as well as its contribution as a prognostic factor for CRC. Nonetheless, our results suggest that the determination of plasma levels of sP-selectin might represent a prognostic parameter in the management of patients with CRC and may help in the choice of more aggressive treatment and/or more strict follow-up procedures in a subgroup of patients who are at high risk of recurrence.
